Not "conjecture" at all. In fact the company has been very forthcoming on the detail of the focus of the SEC and DOJ investigations. The 10Qs are clear that the initial object of the investigation is CoV communications with the investment community and the the FDA. The 1/10/22 10Q reported the expansion of the investigation into the company's communication and (insider) trading around the HIV and mTNBC as well as the company's use of "investor relations" vendors. These are clear and obvious.
There is NOTING in the report about shorts, bashers, etc. in the company reporting, it is just a false interpretation of the SEC's investigation of hedge funds and their shorting activities -- unrelated to the Cytodyn SEC/DOJ investigation.
As the SEC and DOJ have expanded the Cytodyn investigation it will delay the final action timing, but it will very likely still be by mid-2022.
News 
Market Data 
Discover 
AI
